{
    "nctId": "NCT02048059",
    "briefTitle": "ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases",
    "officialTitle": "A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Brain Metastases",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 72,
    "primaryOutcomeMeasure": "Intracranial objective response rate (iORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. \u2265 18 years old\n2. Breast cancer\n3. Recurrent brain metastases from breast cancer\n4. At least one radiologically-confirmed and measurable metastatic brain lesion ( \u2265 0.5 cm)\n5. Neurologically stable\n6. Karnofsky Performance Status (KPS) score \u2265 70\n7. Adequate hematology and serum chemistry laboratory test results\n8. Expected survival of \u2265 3 months\n\nExclusion Criteria:\n\n1. Prior treatment with ANG1005/GRN1005\n2. Evidence of symptomatic intracranial hemorrhage\n3. Pregnancy or lactation\n4. Inadequate bone marrow reserve\n5. Any evidence of severe or uncontrolled diseases\n6. Patients with the presence of an infection including abscess or fistulae, or known infection with hepatitis B or C or HIV\n7. History of interstitial lung disease or evidence of clinically significant interstitial lung disease\n8. Severe cardiac conduction disturbance\n9. Central nervous system (CNS) disease requiring immediate neurosurgery intervention\n10. Known severe hypersensitivity or allergy to paclitaxel or any of its components",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}